Researchers in Sweden have found that a lower dose of a common immunotherapy drug for malignant melanoma can significantly improve outcomes while reducing side effects. Their findings were published today in the Journal of the National Cancer Institute .

Malignant melanoma is the most invasive form of skin cancer, carrying the highest risk of death. While this type of cancer is highly treatable and curable in early stages before the cancer has spread, advanced tumors can be difficult to treat, especially when surgical removal is not an option. These advanced cases are typically treated with antibody-based immunotherapy drugs such as nivolumab and ipilimumab, which have been shown to significantly improve survival rates.

While these immunotherapy drugs are typically administered a

See Full Page